Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
phage FT5P
- Development stage
- Preclinical
- Lead developer
- Centre for Plant Biotechnology and Genomics
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
01
Overview
Phage FT5P is a novel siphovirus bacteriophage isolated from wastewater at Hospital Universitario Puerta de Hierro in Madrid, Spain. It is being investigated for its preclinical therapeutic potential against vancomycin-resistant *Enterococcus faecium* (VREfm) infections, a high-priority nosocomial pathogen. FT5P has a 56 Kbp genome encoding 89 genes, with no lysogeny, toxin, antimicrobial resistance, or virulence genes. In preclinical studies, the phage demonstrated stability across a wide pH range (4.5–10.5) and physiological temperatures, and showed significant antibiofilm activity, preventing up to 70% of biofilm formation and reducing the viability of established biofilms. It also exhibits synergistic interactions when combined with phage FT2P and additive effects with daptomycin.
- Other names
- FT5P phageFT-5P phageFT 5P phage
Beyond the preview
Go deeper on phage FT5P.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on phage FT5P.